GoKawiilMerck-Moderna melanoma vaccine intismeran clears phase III trial with over 1,100 patients
A phase III trial of intismeran, a personalized cancer vaccine developed by Merck and Moderna, showed that melanoma patients who received it had longer recurrence-free survival than those given a placebo. The double-blind study of more than 1,100 participants builds on an earlier phase II trial with 157 patients and moves the vaccine closer to regulatory approval.
GoKawiil's interpretation of the reporting above, not reported fact.
If approved, intismeran would be only the second therapeutic cancer vaccine ever cleared and the first for melanoma, since all cancers carry mutations that such personalized vaccines are designed to target. Success here could accelerate similar trials already underway for lung, bladder and kidney cancers, drawing fresh investment into personalized oncology.
- Phase III trial of over 1,100 patients showed intismeran reduced melanoma recurrence versus placebo
- It would be the first melanoma vaccine and second therapeutic cancer vaccine ever approved
- Ongoing trials are testing the same approach for lung, bladder and kidney cancers
Neutrogena Ultra Sheer Dry-Touch Sunscreen SPF 70 — While researchers race to bring personalized melanoma vaccines to patients, daily broad-spectrum sunscreen remains the simplest melanoma defense you can act on today. Neutrogena's Ultra Sheer formula is lightweight and dry-touch, so it's easy to wear every day under makeup or on the go.
See Neutrogena Ultra Sheer Dry-Touch Sunscreen SPF 70 on Amazon → Affiliate link — we may earn a commission on purchases, at no extra cost to you. Product picked by AI based on this article; it is not a tested recommendation.Source: nature.com — Ott, 2026-08-28
Published there as: “The Moderna cancer vaccine offers hope — now we must speed up personalized therapies”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.